The mission of the University of Michigan is to serve the people of Michigan and the world through preeminence in creating, communicating, preserving, and applying knowledge, art, and academic values, and in developing leaders and citizens who will challenge the present and enrich the future. Why Work at Michigan? Being part of something greater, of serving a larger mission of discovery and care — that's the heart of what drives people to work at Michigan. In some way, great or small, every person here helps to advance this world-class institution. It's adding a purpose to your profession. Work at Michigan and become a victor for the greater good.
New Product & Tech activity — 3 fresh signals just appeared.
The order this company entered each market — oldest to newest
Ascentage Presents Olverembatinib Data at ASCO
Ascentage Pharma Presents Olverembatinib Data at ASCO
Sign up to see the full signal feed
How University Of Michigan's international expansion compares to its competitors
University Of MichiganYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 University Of MichiganYou | 2 | 2 | -25% | 7 | 17 |
Human Resources Customer Care Representative
View postingAnn Arbor, MI · 2d ago
Milk Room Manager
View postingAnn Arbor, MI · 2d ago
Research Analyst
View postingAnn Arbor, MI · last wk.
Helping NASA & Artemis II
Ended
Michigan researchers developed models that forecast solar radiation up to 24 hours ahead, so Artemis missions have more time to respond.
Active
Michigan researchers developed models that forecast solar radiation up to 24 hours ahead, so Artemis missions have more time to respond.
ActiveContinuity Biosciences initiated Phase 1 trial evaluating gemcitabine via IOP platform for pancreatic cancer at major academic centers including WVU Medicine and University of Michigan.
Ascentage Pharma presented updated efficacy and safety data for Olverembatinib (HQP1351) as second-line CML-CP treatment at ASCO 2026, showing 91.3% CCyR and 60.9% MMR at 24 cycles with manageable safety profile.
Ascentage Pharma presented Phase Ib data at ASCO 2026 showing olverembatinib combined with blinatumomab achieved 91% complete response rate in Ph+ BCP-ALL or CML-LBP patients with favorable safety profile.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about University Of Michigan's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
